Evaluating Efficacy and Safety of Disease-Modifying Therapies in Multiple Sclerosis
Friday, 4 October 2024, 10:48
Overview of DMT Efficacy in MS
Recent studies have evaluated the disease-modifying therapies (DMTs) available for multiple sclerosis (MS), focusing on their efficacy and safety profiles. The investigation concentrated on moderate-efficacy DMTs, particularly injectable drugs like dimethyl fumarate and teriflunomide.
Study Findings
- The results indicated that first-line DMTs showed similar efficacy in patients.
- Parameters such as NEDA-2 and NEDA-3 outcomes were critically analyzed.
- Lower rates of persistence were noted with some therapies.
- Discontinuation rates and their impact on disability progression were highlighted.
Conclusion on Efficacy and Safety
Overall, the efficacy and safety of DMTs remain pivotal in the management of MS, guiding treatment decisions and patient care. For in-depth exploration of these findings, further reading on the latest research is suggested.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.